文献速递乳腺癌放疗放疗物理与技术

五分割超低分次全乳放疗联合同步整合加量的五年晚期毒性

Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiotherapy With Simultaneous Integrated Boost: A Prospective Multicentre Cohort Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-10-16

这项前瞻性多中心非随机队列纳入242例早期乳腺癌保乳术后患者,全乳放疗26 Gy分5次,其中157例接受同步整合加量至29 Gy分5次;中位随访64.7个月,加量亚组五年任何级别疼痛累积14.6%、纤维化8.9%,客观晚期不良反应发生率低。

要点

  • 同步整合加量亚组五年任何级别疼痛14.6%、纤维化8.9%,其他晚期反应少见。
  • 探索性分析中加量组疼痛较未加量组更常见,其他晚期反应无显著差异。
  • 非随机分组且疼痛与化疗相关,不能作因果推断,需随机研究验证。

核心结论

  • 五分割全乳放疗联合29 Gy同步整合加量在五年余随访中客观晚期不良反应发生率低、肿瘤学结局令人安心。
  • 加量组持续性低级别乳腺疼痛更常见,但非随机分配及与化疗的关联使因果归因受限。

研究设计与样本

  • 全乳放疗26 Gy分5次,157例接受同步整合加量至29 Gy分5次,主要终点为加量亚组的晚期正常组织不良反应。
  • 采用临床检查、照片记录和LENT-SOMA评分前瞻性评估,与未加量患者的比较为探索性。

主要发现

  • 总体队列与加量亚组中位随访均为64.7个月,242例中221例完成计划的五年访视。
  • 加量亚组五年累积任何级别疼痛14.6%、任何级别纤维化8.9%,乳腺水肿5.1%、上肢水肿0.6%、萎缩1.9%、毛细血管扩张0.6%,未见溃疡。
  • 探索性未校正分析中加量组疼痛比未加量组更常见,其他晚期不良反应无显著差异;化疗也与持续性疼痛相关。

关键数值与推荐

  • 全乳放疗剂量26 Gy分5次,同步整合加量至29 Gy分5次。
  • 晚期不良反应按LENT-SOMA评分前瞻性评估。

临床怎么用

  • 该五分割方案可将治疗缩短至一周,加量后客观晚期不良反应低,可在选定患者中继续谨慎使用。
  • 因疼痛信号及非随机设计,需结合基线症状评估并等待进一步前瞻性随机研究。
  • 治疗决策时应考虑化疗与持续性疼痛的关联。

局限性

  • 非随机分组,加量与否的比较仅为探索性未校正分析。
  • 疼痛与化疗的关联及缺乏基线症状评估,限制因果推断。
  • 部分患者未完成五年访视(242例中221例完成)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ultra-hypofractionated whole-breast radiotherapy has become an accepted option for early breast cancer, but evidence on the incorporation of a simultaneous integrated boost within a five-fraction schedule remains limited. The present study evaluated five-year late side effects after whole-breast irradiation with a simultaneous integrated boost delivered in five fractions in a prospective multicentre cohort. METHODS: This prospective, non-randomized, multicentre cohort included 242 patients with early breast cancer treated between April and December 2020. All patients underwent breast-conserving surgery with clear margins. Whole-breast irradiation was delivered at 26 Gy in five daily fractions, and 157 patients received a simultaneous integrated boost to 29 Gy in five fractions. The primary endpoint was late normal-tissue side effects in the simultaneous integrated boost subgroup, assessed prospectively with clinical examination, photographic documentation, and LENT-SOMA scoring. Comparisons with patients treated without a boost were exploratory. RESULTS: Median follow-up was 64.7 months in both the overall cohort and the simultaneous integrated boost subgroup, and 221 of 242 patients completed the scheduled five-year visit. In the simultaneous integrated boost subgroup, cumulative any-grade pain was reported in 14.6% of patients at five years, and cumulative any-grade fibrosis in 8.9%. Other late side effects were uncommon, including breast oedema in 5.1%, arm oedema in 0.6%, atrophy in 1.9%, and telangiectasia in 0.6%; no ulceration was observed. In exploratory unadjusted analyses, pain was more frequent in the simultaneous integrated boost group than in the no-boost group, whereas no significant differences were observed for other late side effects. Chemotherapy receipt was also associated with persistent pain in exploratory analyses. CONCLUSIONS: Whole-breast irradiation with a 29 Gy simultaneous integrated boost in five fractions achieved low rates of objective late side effects and reassuring oncological outcomes after more than five years, while shortening treatment to a single one-week course compared with sequential or moderately hypofractionated schedules. Persistent low-grade breast pain was more frequent with the boost, but non-randomized allocation and its association with chemotherapy preclude causal attribution, supporting continued, careful use in selected patients alongside further prospective, randomized studies with baseline symptom assessment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dzhugashvili M, Lopez E, Fernández-Ibiza J, et al. Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiotherapy With Simultaneous Integrated Boost: A Prospective Multicentre Cohort Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 42887678. doi:10.1016/j.ijrobp.2026.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。